Welcure Drugs & Pharmaceuticals Ltd
Fundamental Score
Welcure Drugs & Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of WELCURE across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 1.98 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (361.96%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (167.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (214.33% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (94.95% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (193.83% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
7 factors identified
Below-Average Return on Equity (4.18%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.53%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Negative Free Cash Flow (₹-222.01 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Welcure Drugs & Pharmaceuticals Ltd
About WELCURE
Business Overview
Welcure Drugs and Pharmaceuticals Limited engages in trading of medical products in India. The company offers pharmaceutical and agri-tech development solutions. It also imports and exports its products. Welcure Drugs and Pharmaceuticals Limited was incorporated in 1996 and is based in Ahmedabad, India.
Company Details
Key Leadership
Latest News
WELCURE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Welcure Drugs & Pharmaceuticals Ltd (WELCURE)?
As of 29 Jan 2026, 10:37 am IST, Welcure Drugs & Pharmaceuticals Ltd (WELCURE) is currently trading at ₹0.32. The stock has a market capitalization of ₹67.97 (Cr).
Is WELCURE share price Overvalued or Undervalued?
WELCURE is currently trading at a P/E ratio of 1.98x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Welcure Drugs & Pharmaceuticals Ltd share price?
Key factors influencing WELCURE's price include its quarterly earnings growth (Sales Growth: 167.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Welcure Drugs & Pharmaceuticals Ltd a good stock for long-term investment?
Welcure Drugs & Pharmaceuticals Ltd shows a 5-year Profit Growth of 193.83% and an ROE of 4.18%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.92 before investing.
How does Welcure Drugs & Pharmaceuticals Ltd compare with its industry peers?
Welcure Drugs & Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare WELCURE's P/E of 1.98x and ROE of 4.18% against the industry averages to determine its competitive standing.
What is the P/E ratio of WELCURE and what does it mean?
WELCURE has a P/E ratio of 1.98x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹2 for every ₹1 of annual earnings.
How is WELCURE performing according to Bull Run's analysis?
WELCURE has a Bull Run fundamental score of 51.9/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does WELCURE belong to?
WELCURE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Welcure Drugs & Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for WELCURE?
WELCURE has an ROE of 4.18%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Welcure Drugs & Pharmaceuticals Ltd generates profits from shareholders' equity.
How is WELCURE's debt-to-equity ratio and what does it indicate?
WELCURE has a debt-to-equity ratio of 0.92, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is WELCURE's dividend yield and is it a good dividend stock?
WELCURE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has WELCURE grown over the past 5 years?
WELCURE has achieved 5-year growth rates of: Sales Growth 214.33%, Profit Growth 193.83%, and EPS Growth 94.95%.
What is the promoter holding in WELCURE and why does it matter?
Promoters hold 0.00% of WELCURE shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is WELCURE's market capitalization category?
WELCURE has a market capitalization of ₹68 crores, placing it in the Small-cap category.
How volatile is WELCURE stock?
WELCURE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for WELCURE?
WELCURE has a 52-week high of ₹N/A and low of ₹N/A.
What is WELCURE's operating profit margin trend?
WELCURE has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is WELCURE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 167.29% and YoY Profit Growth of 361.96%.
What is the institutional holding pattern in WELCURE?
WELCURE has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.